PharmNovo AB is pleased to announce that the company has strengthened the team when entering the clinical phase with PN6047. Tommy Nilsson takes on the role of CFO, and Jarkko Kalliomäki will support clinical management and work with the design and development of clinical studies.

In August, PharmNovo started clinical studies of its drug candidate PN6047 for the treatment of neuropathic pain, so-called nerve pain, after raising SEK 73 million in an issue led by Sciety earlier this summer.

Tommy Nilsson has a background as CFO at subsidiaries of Electrolux and Ericsson. He has worked as interim CFO for businesses in several industries for the past years. At PharmNovo, he will lead financial management and reporting, build up the company's routines and processes, and prepare the company for future follow-on financing.

Jarkko Kalliomäki is a specialist in pain and pain relief and holds an MD in Physiology. He has over ten years of experience as a Senior Clinical Research Physician at AstraZeneca R&D in Södertälje in several pain-related projects. He works as a consultant in rehabilitation medicine and pain relief at, among others, Sophiahemmet, PBM, and St. Göran's Hospital. Jarkko will support clinical management and work with the design and development of the clinical studies in close collaboration with Olof Breuer, CMO at PharmNovo.

Press release

LinkedIn